Generic Name: Insulin (oral formulation)
Experimental Code: ORMD-0801
Dosage Form: Capsule (oral)
Current Status: Phase II/III Clinical Trials
Indications
-
Type 2 Diabetes Mellitus (T2DM) patients requiring insulin therapy.
-
Potential use in patients delaying transition to injectable insulin.
Dosage & Administration (in trials)
-
Capsules administered twice daily for 28 days.
-
Exact therapeutic dose not finalized.
Safety & Side Effects
-
Common: Mild gastrointestinal discomfort.
-
Rare: Hypoglycemia (low blood sugar) not commonly observed.
-
Long-term safety profile still under investigation.
Future Prospects
-
If approved, ORMD-0801 could become the first commercial oral insulin capsule, replacing injections for millions of diabetes patients.